SDX 102Alternative Names: Alanosine; L-alanosine; NSC-153353
Latest Information Update: 25 May 2007
At a glance
- Originator National Cancer Institute (USA); University of California, San Diego
- Developer Salmedix
- Class Cytostatic antibiotics
- Mechanism of Action Adenylosuccinate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Brain cancer; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma